Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Regulus Therapeutics Inc. (RGLS)  
$2.09 0.12 (5.43%) as of 4:30 Mon 5/13


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 145,981,000
Market Cap: 305.10(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $1.13 - $2.88
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Regulus Therapeutics is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat diseases. Co.'s key product candidates are RG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. Co. has multiple programs in various stages of preclinical development including RGLS5579 as a clinical candidate in its glioblastoma multiforme program, its preclinical programs targeting the Hepatitis B virus and Non-Alcoholic Steatohepatitis program.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 0 25,516 25,516 25,516
Total Sell Value $0 $30,379 $30,379 $30,379
Total People Sold 0 3 3 3
Total Sell Transactions 0 3 3 3
End Date 2024-02-11 2023-11-10 2023-05-12 2022-05-12

   
Records found: 306
  Page 8 of 13  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Parshall B Lynne Director   –       •       •   2014-10-22 4 AS $14.00 $1,533,125 D/D (109,534) 6,799,266     -
   Alnylam Pharmaceuticals, Inc. 10% Owner   –       –       •   2014-10-22 4 AS $14.00 $1,533,125 D/D (109,534) 5,900,266     -
   Xanthopoulos Kleanthis G President and CEO   •       •      –    2014-10-20 4 AS $7.00 $2,100 D/D (300) 2,466     -
   Xanthopoulos Kleanthis G President and CEO   •       •      –    2014-10-20 4 OE $0.38 $114 D/D 300 2,766     -
   Xanthopoulos Kleanthis G President and CEO   •       •      –    2014-10-17 4 AS $7.04 $2,816 D/D (400) 2,466     -
   Xanthopoulos Kleanthis G President and CEO   •       •      –    2014-10-17 4 OE $0.38 $152 D/D 400 2,866     -
   Parshall B Lynne Director   –       •       •   2014-10-17 4 AS $6.79 $20,371 D/D (3,000) 6,908,800     -
   Alnylam Pharmaceuticals, Inc. 10% Owner   –       –       •   2014-10-17 4 AS $6.79 $20,371 D/D (3,000) 6,009,800     -
   Parshall B Lynne Director   –       •       •   2014-10-16 4 AS $6.76 $32,450 D/D (4,800) 6,911,800     -
   Alnylam Pharmaceuticals, Inc. 10% Owner   –       –       •   2014-10-16 4 AS $6.76 $32,450 D/D (4,800) 6,012,800     -
   Parshall B Lynne Director   –       •       •   2014-10-15 4 AS $6.67 $28,687 D/D (4,300) 6,916,600     -
   Alnylam Pharmaceuticals, Inc. 10% Owner   –       –       •   2014-10-15 4 AS $6.67 $28,687 D/D (4,300) 6,017,600     -
   Xanthopoulos Kleanthis G President and CEO   •       •      –    2014-10-14 4 AS $7.00 $2,800 D/D (400) 2,466     -
   Xanthopoulos Kleanthis G President and CEO   •       •      –    2014-10-14 4 OE $0.38 $152 D/D 400 2,866     -
   Alnylam Pharmaceuticals, Inc. 10% Owner   –       –       •   2014-10-10 4 AS $6.41 $12,813 D/D (2,000) 6,021,900     -
   Parshall B Lynne Director   –       •       •   2014-10-10 4 AS $6.41 $12,813 D/D (2,000) 6,920,900     -
   Xanthopoulos Kleanthis G President and CEO   •       •      –    2014-10-09 4 AS $7.00 $735 D/D (105) 2,466     -
   Xanthopoulos Kleanthis G President and CEO   •       •      –    2014-10-09 4 OE $0.38 $40 D/D 105 2,571     -
   Alnylam Pharmaceuticals, Inc. 10% Owner   –       –       •   2014-10-09 4 AS $6.58 $31,238 D/D (4,750) 6,023,900     -
   Parshall B Lynne Director   –       •       •   2014-10-09 4 AS $6.58 $31,238 D/D (4,750) 6,922,900     -
   Alnylam Pharmaceuticals, Inc. 10% Owner   –       –       •   2014-10-08 4 AS $6.63 $21,888 D/D (3,300) 6,028,650     -
   Parshall B Lynne Director   –       •       •   2014-10-08 4 AS $6.63 $21,888 D/D (3,300) 6,927,650     -
   Alnylam Pharmaceuticals, Inc. 10% Owner   –       –       •   2014-10-03 4 AS $6.88 $22,688 D/D (3,300) 6,031,950     -
   Parshall B Lynne Director   –       •       •   2014-10-03 4 AS $6.88 $22,688 D/D (3,300) 6,930,950     -
   Alnylam Pharmaceuticals, Inc. 10% Owner   –       –       •   2014-10-02 4 AS $6.64 $24,903 D/D (3,750) 6,035,250     -
  306 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 8 of 13
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us